Press Release Details

Cerus Corporation Added to Nasdaq Biotechnology Index

May, 16 2006

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that the company has been selected to be included in the NASDAQ Biotechnology Index(R) (NASDAQ:NBI) effective with the market open on Monday, May 22, 2006.

"We are pleased to join the Nasdaq Biotechnology Index and believe that our addition to the Index is further recognition of the Company's achievements, steady growth, and overall performance," said Claes Glassell, President and CEO of Cerus Corporation.

Launched in 1993, the NASDAQ Biotech Index includes companies that are classified as biotechnology or pharmaceutical according to the FTSE(TM) Global Classification System. All securities in the Index are listed on the NASDAQ National Market and meet minimum requirements including market value, average daily share volume and seasoning as a public company, among other criteria. The Index is ranked on a semi-annual basis in May and November and is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Amex:IBB). In addition, options based on the NASDAQ Biotechnology Index and iShares Nasdaq Biotechnology Index Fund trade on various exchanges.


Cerus Corporation is developing and commercializing novel, proprietary products and technologies within the fields of immunotherapy and blood safety that are intended to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

Statements in this news release are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainties related to manufacturing, product demand and market acceptance and adoption of any products, competitive conditions, internal and external factors that could impact commercialization, actions by regulatory authorities and other government authorities, including the FDA and foreign counterparts, at any stage of the development, marketing or commercialization process, the determination of reimbursement rates for the company's products, the ability to identify, hire and retain qualified sales and marketing personnel, the initiation, timing and results of clinical trials and other development activities, the acceptability of any data by regulatory authorities, technological advances in the medical field, additional financing activities, and other factors discussed in the company's filings with the Securities and Exchange Commission. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise; all forward-looking statements speak only as of the time when made.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600